What is Qalsody?
Qalsody is the brand name for tofersen, a treatment for amyotrophic lateral sclerosis (ALS) associated with certain genetic mutations. It’s designed for people whose ALS involves the SOD1 gene mutation.
Who is it for (which ALS type)?
Qalsody is used in SOD1-ALS, meaning ALS cases where testing shows an SOD1 mutation.
How does Qalsody work?
Tofersen targets the underlying biology of SOD1-ALS by using an antisense mechanism to reduce the production of the mutant SOD1 protein, which is thought to drive disease processes in SOD1-linked ALS.
How is Qalsody given?
Qalsody is administered by intrathecal injection (delivered into the spinal fluid), which means treatment requires clinical administration.
What should people ask about before starting?
People considering Qalsody typically need to confirm:
- whether they have an SOD1 mutation (not all ALS is SOD1-ALS)
- that their neurology team can safely provide intrathecal dosing
- what monitoring is planned around treatment, since this route can require specific follow-up
Are there patents or exclusivity details for Qalsody/tofersen?
If you’re looking for patent and exclusivity information related to tofersen (Qalsody), DrugPatentWatch.com is a useful place to check current filings and status: https://www.drugpatentwatch.com/
What else might be needed to answer your exact question?
“Qalsody” can mean different things depending on what you want to know (approval status, dosing schedule, side effects, pricing, patents, or competition). Tell me what angle you’re after—like “side effects,” “FDA approval,” “cost,” or “patent expiry”—and I’ll focus the answer.
Sources:
- [1] https://www.drugpatentwatch.com/